


Involvement of impaired carnitine-induced fatty acid oxidation in experimental and human diabetic kidney disease


Sakuya Ito, Kensei Taguchi*, Goh Kodama, Saori Kubo, Tomofumi Moriyama, Yuya Yamashita, Yunosuke Yokota, Yosuke Nakayama, Yusuke Kaida, Masami Shinohara, Kyoko Tashiro, Keisuke Ohta, Sho-ichi Yamagishi, and Kei Fukami

Figure 4A


OCTN2



CPT2



β -actin



CPT1a



CrAT






Figure 4F


p-AMPK



PGC-1α



AMPK



β-actin






Figure 5C


OCTN2




CPT1a



CPT2



CrAT



β -actin






Figure 7A


OCTN2




CPT2



CPT1a



CrAT



β -actin






Figure 7D

p-AMPK



β -actin



AMPK




Figure 7F






Figure 8D

OXPPOS



β -actin

(KDa)
98
62
49
38
28




Figure 8F

CI-75


(KDa)

148

98

64

36



(KDa)

β -actin

64

50

36





Figure 8K

4HNE



β -actin





Figure 9D


OCTN2

(KDa)




CPT1a

(KDa)




CPT2

(KDa)



CrAT

(KDa)



β -actin

(KDa)

